Integrative bioinformatics and machine learning approach unveils potential biomarkers linking coronary atherosclerosis and fatty acid metabolism-associated gene.

BACKGROUND

Atherosclerosis (AS) is increasingly recognized as a chronic inflammatory disease that significantly compromises vascular health and acts as a major contributor to cardiovascular diseases. Advancements in lipidomics and metabolomics have unveiled the complex role of fatty acid metabolism (FAM) in both healthy and pathological states. However, the specific roles of fatty acid metabolism-related genes (FAMGs) in shaping therapeutic approaches, especially in AS, remain largely unexplored and are a subject of ongoing research.

METHODS

This study employed advanced bioinformatics techniques to identify and validate FAMGs associated with AS. We conducted differential expression analysis on a select list of 49 candidate FAMGs. GSEA and GSVA were utilized to elucidate the potential biological roles and pathways of these FAMGs. Subsequently, Lasso regression and SVM-RFE were applied to identify key hub genes and assess the diagnostic efficacy of seven FAMGs in distinguishing AS. The study also explored the correlation between these hub FAMGs and clinical features of AS. Validation of the expression levels of the seven FAMGs was performed using datasets GSE43292 and GSE9820.

RESULTS

The study pinpointed seven FAMGs with a close association to AS: ACSBG2, ELOVL4, ACSL3, CPT2, ALDH2, HSD17B10, and CPT1B. Analysis of their biological functions underscored their significant involvement in critical processes such as fatty acid metabolism, small molecule catabolism, and nucleoside bisphosphate metabolism. The diagnostic potential of these seven FAMGs in AS differentiation showed promising results.

CONCLUSIONS

This research has successfully identified seven key FAMGs implicated in AS, offering novel insights into the pathophysiology of the disease. These findings not only contribute to our understanding of AS but also present potential biomarkers for the disease, opening avenues for more effective monitoring and progression tracking of AS.